Direct molecular evidence for both multicentric and monoclonal carcinogenesis followed by transdifferentiation from hepatocellular carcinoma to cholangiocarcinoma in a case of metachronous liver cancer

Ohni,Sumie; Ohni,Sumie; Yamaguchi,Hiromi; Yamaguchi,Hiromi; Hirotani,Yukari; Hirotani,Yukari; Nakanishi,Yoko; Nakanishi,Yoko; Midorikawa,Yutaka; Midorikawa,Yutaka; Sugitani,Masahiko; Sugitani,Masahiko; Naruse,Hiromu; Naruse,Hiromu; Nakayama,Tomohiro; Nakayama,Tomohiro; Makishima,Makoto; Makishima,Makoto; Esumi,Mariko; Esumi,Mariko

doi:10.3892/ol.2021.13140

Direct molecular evidence for both multicentric and monoclonal carcinogenesis followed by transdifferentiation from hepatocellular carcinoma to cholangiocarcinoma in a case of metachronous liver cancer

Authors:
- Sumie Ohni
- Hiromi Yamaguchi
- Yukari Hirotani
- Yoko Nakanishi
- Yutaka Midorikawa
- Masahiko Sugitani
- Hiromu Naruse
- Tomohiro Nakayama
- Makoto Makishima
- Mariko Esumi
View Affiliations

Affiliations: Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo 173‑8610, Japan, Division of Biochemistry, Department of Biomedical Sciences, Nihon University School of Medicine, Tokyo 173‑8610, Japan, Department of Surgery, Nihon University School of Medicine, Tokyo 173‑8610, Japan
Published online on: November 17, 2021 https://doi.org/10.3892/ol.2021.13140
Article Number: 22
Copyright: © Ohni et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Frequent recurrence is a major issue in liver cancer and histological heterogeneity frequently occurs in this cancer type. However, it has remained elusive whether such cancers are multicentric or monoclonal. To elucidate the clonal evolution of hepatocellular carcinoma (HCC) recurrence and combined hepatocellular‑cholangiocarcinoma (cHCC‑CCA) development, the somatic mutation frequency and signatures in a patient with triple occurrence of liver cancer every three years were examined, with samples designated as #1HCC, #2HCC and #3cHCC‑CCA, respectively. A total of four tumor regions, including HCC (#3HCC) and intrahepatic CCA (#3iCCA) components of #3cHCC‑CCA, and three nontumor regions (#1N, #2N and #3N) were precisely dissected from formalin‑fixed paraffin‑embedded tissues of each surgical specimen. DNA was extracted and subjected to tumor‑specific somatic mutation determination. Of note, five nonsynonymous single‑nucleotide variants (SNVs), namely those of KMT2D, TP53, DNMT3A, PKHD1 and TLR4, were identified in #3cHCC‑CCA. All five SNVs were detected in both #3HCC and #3iCCA and #2HCC but not in #1HCC. The telomerase reverse transcriptase (TERT) promoter mutation C228T, but not C250T, was observed in all tumors. Digital PCR of C228T also indicated the presence of the TERT promoter mutation C228T in nontumorous liver tissues (#1N, #2N and #3N) at a frequency of 0.11‑0.83% compared with normal liver and blood samples. These results suggest the following phylogenetic evolution of three metachronous liver cancers: #1HCC was not related to #2HCC, #3HCC and #3iCCA; both #3HCC and #3iCCA arose from #2HCC. From the above, three novel findings were deduced: i) Both multicentric occurrence and intrahepatic metastasis may be involved in liver cancer in a three‑year interval; ii) transdifferentiation from HCC to iCCA is a possible pathogenic mechanism of cHCC‑CCA; and iii) a nontumorous, noncirrhotic liver may contain a preneoplastic region with a cancer driver mutation in the TERT promoter.

View Figures

View References

1	Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
2	Vilarinho S and Calvisi DF: New advances in precision medicine for hepatocellular carcinoma recurrence prediction and treatment. Hepatology. 60:1812–1814. 2014. View Article : Google Scholar : PubMed/NCBI
3	Feo F and Pascale RM: Multifocal hepatocellular carcinoma: Intrahepatic metastasis or multicentric carcinogenesis? Ann Transl Med. 3:42015.PubMed/NCBI
4	Yang SL, Luo YY, Chen M, Zhou YP, Lu FR, Deng DF and Wu YR: A systematic review and meta-analysis comparing the prognosis of multicentric occurrence and vs. intrahepatic metastasis in patients with recurrent hepatocellular carcinoma after hepatectomy. HPB (Oxford). 19:835–842. 2017. View Article : Google Scholar : PubMed/NCBI
5	Furuta M, Ueno M, Fujimoto A, Hayami S, Yasukawa S, Kojima F, Arihiro K, Kawakami Y, Wardell CP, Shiraishi Y, et al: Whole genome sequencing discriminates hepatocellular carcinoma with intrahepatic metastasis from multi-centric tumors. J Hepatol. 66:363–373. 2017. View Article : Google Scholar : PubMed/NCBI
6	Sempoux C, Kakar S, Kondo F and Schirmacher P: Combined hepatocellular-cholangiocarcinoma and undifferentiated primary liver carcinoma. WHO classification of tumours of the digestive system. Bosman FT, Garneiro F, Hruban RH and Theise ND: IARC; Lyon: pp. 260–262. 2019
7	Nagahama Y, Sone M, Chen X, Okada Y, Yamamoto M, Xin B, Matsuo Y, Komatsu M, Suzuki A, Enomoto K and Nishikawa Y: Contributions of hepatocytes and bile ductular cells in ductular reactions and remodeling of the biliary system after chronic liver injury. Am J Pathol. 184:3001–3012. 2014. View Article : Google Scholar : PubMed/NCBI
8	Sia D, Villanueva A, Friedman SL and Llovet JM: Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. 152:745–761. 2017. View Article : Google Scholar : PubMed/NCBI
9	Chiba T, Zheng YW, Kita K, Yokosuka O, Saisho H, Onodera M, Miyoshi H, Nakano M, Zen Y, Nakanuma Y, et al: Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. Gastroenterology. 133:937–950. 2007. View Article : Google Scholar : PubMed/NCBI
10	Fujimoto A, Furuta M, Totoki Y, Tsunoda T, Kato M, Shiraishi Y, Tanaka H, Taniguchi H, Kawakami Y, Ueno M, et al: Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat Genet. 48:500–509. 2016. View Article : Google Scholar : PubMed/NCBI
11	Wang A, Wu L, Lin J, Han L, Bian J, Wu Y, Robson SC, Xue L, Ge Y, Sang X, et al: Whole-exome sequencing reveals the origin and evolution of hepato-cholangiocarcinoma. Nat Commun. 9:8942018. View Article : Google Scholar : PubMed/NCBI
12	Nakayama Y, Yamaguchi H, Einaga N and Esumi M: Pitfalls of DNA quantification using DNA-binding fluorescent dyes and suggested solutions. PLoS One. 11:e01505282016. View Article : Google Scholar : PubMed/NCBI
13	Einaga N, Yoshida A, Noda H, Suemitsu M, Nakayama Y, Sakurada A, Kawaji Y, Yamaguchi H, Sasaki Y, Tokino T and Esumi M: Assessment of the quality of DNA from various formalin-fixed paraffin-embedded (FFPE) tissues and the use of this DNA for next-generation sequencing (NGS) with no artifactual mutation. PLoS One. 12:e01762802017. View Article : Google Scholar : PubMed/NCBI
14	Ward JH Jr: Hierarchical grouping to optimize an objective function. J Am Stat Assoc. 58:236–244. 1963. View Article : Google Scholar
15	Edmondson HA and Steiner PE: Primary carcinoma of the liver: A study of 100 cases among 48,900 necropsies. Cancer. 7:462–503. 1954. View Article : Google Scholar : PubMed/NCBI
16	Nakanuma Y, Klimstra DS, Komuta M and Zen Y: Intrahepatic cholangiocarcinoma. WHO Classification of Tumours of the Digestive System. Bosman FT, Carneiro F, Hruban RH and Theise ND: IARC; Lyon: pp. 254–259. 2019
17	Huang Zy, Liang By, Xiong M, Zhan DQ, Wei S, Wang GP, Chen YF and Chen XP: Long-term outcomes of repeat hepatic resection in patients with recurrent hepatocellular carcinoma and analysis of recurrent types and their prognosis: A single-center experience in China. Ann Surg Oncol. 19:2515–2525. 2012. View Article : Google Scholar : PubMed/NCBI
18	Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N and Stewart A: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 366:883–892. 2012. View Article : Google Scholar : PubMed/NCBI
19	Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JM, Papaemmanuil E, Brewer DS, Kallio HM, Högnäs G, Annala M, et al: The evolutionary history of lethal metastatic prostate cancer. Nature. 520:353–357. 2015. View Article : Google Scholar : PubMed/NCBI
20	Yamamoto S, Midorikawa Y, Nagae G, Tatsuno K, Ueda H, Moriyama M, Takayama T and Aburatani H: Spatial and temporal expansion of intrahepatic metastasis by molecularly-defined clonality in multiple liver cancers. Cancer Sci. 111:601–609. 2020. View Article : Google Scholar : PubMed/NCBI
21	Joseph NM, Tsokos CG, Umetsu SE, Shain AH, Kelley RK, Onodera C, Bowman S, Talevich E, Ferrell LD, Kakar S and Krings G: Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma. J Pathol. 248:164–178. 2019. View Article : Google Scholar : PubMed/NCBI
22	Xue R, Chen L, Zhang C, Fujita M, Li R, Yan SM, Ong CK, Liao X, Gao Q, Sasagawa S, et al: Genomic and transcriptomic profiling of combined hepatocellular and intrahepatic cholangiocarcinoma reveals distinct molecular subtypes. Cancer Cell. 35:932–947 e938. 2019. View Article : Google Scholar : PubMed/NCBI
23	Hill MA, Alexander WB, Guo B, Kato Y, Patra K, O'Dell MR, McCall MN, Whitney-Miller CL, Bardeesy N and Hezel AF: Kras and Tp53 mutations cause cholangiocyte- and hepatocyte-derived cholangiocarcinoma. Cancer Res. 78:4445–4451. 2018. View Article : Google Scholar : PubMed/NCBI
24	Seehawer M, Heinzmann F, D'Artista L, Harbig J, Roux PF, Hoenicke L, Dang H, Klotz S, Robinson L, Doré G, et al: Necroptosis microenvironment directs lineage commitment in liver cancer. Nature. 562:69–75. 2018. View Article : Google Scholar : PubMed/NCBI
25	Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, et al: Frequency of TERT promoter mutations in human cancers. Nat Commun. 4:21852013. View Article : Google Scholar : PubMed/NCBI
26	Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, Laurent A, Cherqui D, Balabaud C and Zucman-Rossi J: High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun. 4:22182013. View Article : Google Scholar : PubMed/NCBI
27	Totoki Y, Tatsuno K, Covington KR, Ueda H, Creighton CJ, Kato M, Tsuji S, Donehower LA, Slagle BL, Nakamura H, et al: Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet. 46:1267–1273. 2014. View Article : Google Scholar : PubMed/NCBI
28	Fujimoto A, Furuta M, Shiraishi Y, Gotoh K, Kawakami Y, Arihiro K, Nakamura T, Ueno M, Ariizumi SI, Nguyen HH, et al: Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity. Nat Commun. 6:61202015. View Article : Google Scholar : PubMed/NCBI
29	Kim SK, Takeda H, Takai A, Matsumoto T, Kakiuchi N, Yokoyama A, Yoshida K, Kaido T, Uemoto S, Minamiguchi S, et al: Comprehensive analysis of genetic aberrations linked to tumorigenesis in regenerative nodules of liver cirrhosis. J Gastroenterol. 54:628–640. 2019. View Article : Google Scholar : PubMed/NCBI